» Articles » PMID: 1483945

P53 Gene Mutations Associated with Anaplastic Transformation of Human Thyroid Carcinomas

Overview
Specialty Oncology
Date 1992 Dec 1
PMID 1483945
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Anaplastic carcinoma of the thyroid gland, which is one of the most aggressive, malignant tumors in humans, is considered to originate from preexisting differentiated thyroid cancer. To define the genetic alterations associated with such progression, we examined nine cases of anaplastic thyroid carcinoma for mutation in exons 4-9 of the p53 tumor suppressor gene. Preliminary screening for mutation by RNase protection analysis demonstrated that two out of nine anaplastic carcinomas contained sequence alterations in the p53 gene. Subsequent DNA sequencing identified the mutated nucleotides in these two cases; one was a nonsense mutation at codon 165, and the other was a single-base deletion at codon 176 resulting in the creation of a stop codon downstream due to frameshift. The fact that no mutations were detected in coexisting foci of papillary carcinomas from the same patients shows that these mutations of the p53 gene occurred after development of papillary carcinomas. These results suggest that p53 gene mutation triggers the progression from differentiated into anaplastic carcinoma in the human thyroid gland.

Citing Articles

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.

Lee M, Morris L Oncotarget. 2024; 15:36-48.

PMID: 38275291 PMC: 10812235. DOI: 10.18632/oncotarget.28544.


Progress in Thyroid Cancer Genomics: A 40-Year Journey.

Fagin J, Nikiforov Y Thyroid. 2023; 33(11):1271-1286.

PMID: 37668657 PMC: 10664575. DOI: 10.1089/thy.2023.0045.


Radiotherapy combined with immunotherapy successfully treated one case of anaplastic thyroid cancer: A case report.

Xing Y, Wang Y, Wu X Front Oncol. 2023; 13:1125226.

PMID: 37256174 PMC: 10225731. DOI: 10.3389/fonc.2023.1125226.


2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Bible K, Kebebew E, Brierley J, Brito J, Cabanillas M, Clark Jr T Thyroid. 2021; 31(3):337-386.

PMID: 33728999 PMC: 8349723. DOI: 10.1089/thy.2020.0944.


Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.

Xu B, Qin T, Yu J, Giordano T, Sartor M, Koenig R J Biol Chem. 2020; 295(26):8834-8845.

PMID: 32398261 PMC: 7324504. DOI: 10.1074/jbc.RA120.013530.


References
1.
Jereb B, Stjernsward J, Lowhagen T . Anaplastic giant-cell carcinoma of the thyroid. A study of treatment and prognosis. Cancer. 1975; 35(5):1293-5. DOI: 10.1002/1097-0142(197505)35:5<1293::aid-cncr2820350504>3.0.co;2-w. View

2.
Venkatesh Y, Ordonez N, Schultz P, HICKEY R, Goepfert H, SAMAAN N . Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990; 66(2):321-30. DOI: 10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a. View

3.
Del Sal G, Manfioletti G, Schneider C . The CTAB-DNA precipitation method: a common mini-scale preparation of template DNA from phagemids, phages or plasmids suitable for sequencing. Biotechniques. 1989; 7(5):514-20. View

4.
Foti A, Ahuja H, Allen S, Koduru P, Schuster M, SCHULMAN P . Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood. 1991; 77(11):2441-4. View

5.
Rosai J, Carcangiu M . Pathology of thyroid tumors: some recent and old questions. Hum Pathol. 1984; 15(11):1008-12. DOI: 10.1016/s0046-8177(84)80242-7. View